Assay Transfers Across Sites: Bias and Parity



Assay Transfers Across Sites: Bias and Parity

Published on 29/11/2025

Assay Transfers Across Sites: Bias and Parity

Introduction to Biosimilar Analytical Comparability

The pharmaceutical industry increasingly relies on biosimilars to improve patient access to biologic therapies. Ensuring biosimilar analytical comparability is crucial for regulatory approvals, as it demonstrates that the biosimilar product is similar in quality, safety, and efficacy to the reference biologic. A systematic approach to comparability assessments is essential, especially when transferring assays across different sites.

This article serves as a comprehensive guide to the core components of biosimilar analytical comparability, focusing on CQA mapping, fingerprint analytics, process drift monitoring, and equivalence testing. We will also discuss the role of bridging justifications and strategies for establishing a robust PPQ CPV strategy for biosimilars, as per guidelines established by authorities like the FDA and EMA.

Step 1: Understanding Critical Quality Attributes (CQA) Mapping

The first step in ensuring biosimilar analytical comparability involves defining and mapping Critical Quality Attributes (CQA). This is a fundamental process that involves identifying attributes critical to the product’s quality and efficacy. CQA mapping correlates analytical data with the desired performance of the biosimilar relative to the reference product.

Typically, this mapping includes:

  • Biological activity: Assessed through appropriate functional assays.
  • Purity and impurity profiles: Characterized by advanced separation techniques like HPLC.
  • Physicochemical properties: Including molecular weight, charge, and glycosylation patterns.
  • Stability: Effect of storage and formulation conditions over time.

Implementing a robust CQA mapping process enables a clear understanding of all attributes that may affect therapeutic outcomes. The insights gained from this analysis form a solid foundation for subsequent equivalence testing and any necessary bridging justifications.

Step 2: Establishing a Fingerprint Analytics Framework

Fingerprint analytics provides a deep-dive comparative analysis that characterizes the biosimilar in terms of its structural and functional properties. By developing a reliable analytical fingerprint, developers can identify subtle differences that may impact performance. This requires a combination of various analytical methods, including:

  • Mass spectrometry: Helps in identifying and quantifying proteins and their modifications.
  • Nuclear magnetic resonance (NMR): Assists in providing insights into molecular structure and dynamics.
  • Chromatographic techniques: Such as size exclusion chromatography (SEC) for average molecular weight determinations.

Fingerprint analytics can also facilitate process drift monitoring, empowering quality teams to assess the manufacturing consistency in different production sites over time. Any observed variations can be mapped to the corresponding CQA, ensuring that any issue is addressed promptly.

Step 3: Implementing Process Drift Monitoring

Process drift monitoring involves continuous surveillance of manufacturing processes to ensure ongoing compliance with quality standards. It helps in identifying trends that may signal a deviation from established baselines. The monitoring can utilize statistical process control charts and stability analyses, aiding in proactive management of potential issues.

Effective drift monitoring also incorporates:

  • Regular trend evaluations: Comparing current data against historical data.
  • Deviation management: Immediate investigation of data points that exceed established control limits.
  • Root cause analysis: Implement corrective actions efficiently to restore process control.

By embedding process drift monitoring into the quality management framework, organizations can facilitate meaningful and timely adjustments to prevent non-compliance that could jeopardize regulatory outcomes.

Step 4: Equivalence Testing That Meets Regulatory Standards

Equivalence testing serves as a critical evaluation tool to compare the biosimilar to its reference product. The goal is to demonstrate that any differences in quality attributes do not affect the overall therapeutic equivalence. This testing requires a combination of analytical and functional studies to produce a comprehensive assessment of comparability.

Key elements of equivalence testing include:

  • Statistical analysis: Determining whether equivalency is achieved based on specified margins.
  • Analytical method validation: Ensuring that all techniques used are robust and reproducible.
  • Clinical relevance assessments: Evaluating if the observed variations can impact patient outcomes.

During equivalence testing, teams must align their methodologies with current FDA/EMA guidelines, ensuring that both regulatory and scientific rigor are maintained throughout the process.

Step 5: Justifying Bridging Data for Regulatory Submissions

Bridging justifications are necessary when there are variations in the manufacturing processes or analytical methods employed between sites. The purpose of bridging is to establish confidence that despite differences, the biosimilar product maintains its quality, safety, and efficacy.

The justification must include:

  • Scientific rationale: Clear justification of why the proposed bridging approach is valid.
  • Comparative data: Comprehensive data showing comparative analyses between processes or sites.
  • Regulatory alignment: Demonstrating adherence to guidelines set forth by regulatory agencies, such as WHO and PIC/S.

This documented justification will play a crucial role in regulatory submissions, helping to alleviate concerns about potential variability and ensuring smooth approval processes.

Step 6: Developing a PPQ CPV Strategy for Biosimilars

A robust Process Performance Qualification (PPQ) and Continued Process Verification (CPV) strategy is essential for ensuring ongoing quality throughout the lifecycle of a biosimilar product. The PPQ phase assesses process consistency, while CPV monitors the process to confirm its control and stability.

The strategy should include:

  • Defining the PPQ criteria: Establishing acceptance criteria for the batch release based on CQA mapping and fingerprint analytics.
  • Implementation of CPV plans: Regular data collection and trend analysis using defined metrics to ensure that variations are within acceptable limits.
  • Feedback loops: Incorporating findings into regular review processes for continuous improvement.

Establishing this strategy demonstrates a commitment to quality throughout the biosimilar’s lifecycle, aligning with global regulatory expectations and enhancing overall patient safety.

Conclusion and Summary

The transfer of assays across sites in support of biosimilar development is a complex but critical process. Through a structured approach encompassing CQA mapping, fingerprint analytics, process drift monitoring, equivalence testing, and bridging justifications, organizations can achieve comparability that meets regulatory expectations.

Furthermore, developing a comprehensive PPQ CPV strategy reinforces the commitment to quality, ensuring that biosimilars maintain high standards throughout their lifecycle. By adhering to guidelines from regulatory bodies and employing rigorous analytical methodologies, pharmaceutical professionals can confidently navigate the biosimilar development landscape.